BGI GENOMICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.26 CNY | +0.62% |
|
+0.15% | -18.21% |
| May. 20 | US Legislation Banning Chinese Biotech Firms Will Suppress Legislation, BGI Says | MT |
| May. 10 | Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023 | CI |
| Sales 2022 | 7.05B 973M | Sales 2023 | 4.35B 601M | Capitalization | 19.68B 2.72B |
|---|---|---|---|---|---|
| Net income 2022 | 803M 111M | Net income 2023 | 92M 12.7M | EV / Sales 2022 | 2.13 x |
| Net cash position 2022 | 6.21B 857M | Net cash position 2023 | 5.12B 707M | EV / Sales 2023 | 3.35 x |
| P/E ratio 2022 |
26.4
x | P/E ratio 2023 |
213
x | Employees | - |
| Yield 2022 |
1.93% | Yield 2023 |
0.21% | Free-Float | 52.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.62% | ||
| 1 week | +0.15% | ||
| 1 month | -4.55% | ||
| 3 months | -11.22% | ||
| 6 months | -24.03% | ||
| Current year | -18.21% |
1 week
38.69
39.74
1 month
38.6944.36
Current year
33.0048.30
1 year
33.0062.97
3 years
33.00130.26
5 years
33.00199.40
10 years
16.37261.99
| Managers | Title | Age | Since |
|---|---|---|---|
Li Jian Zhao
CEO | Chief Executive Officer | - | 21-06-15 |
Jian Hua Wang
FOU | Founder | 70 | - |
Yu Jue Wang
DFI | Director of Finance/CFO | 46 | 21-06-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Hua Wang
FOU | Founder | 70 | - |
Hong Tao Wang
BRD | Director/Board Member | - | 16-03-28 |
Ye Yin
BRD | Director/Board Member | 45 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 39.26 | +0.62% | 2,016,377 |
| 24-05-30 | 39.02 | +0.13% | 1,778,155 |
| 24-05-29 | 38.97 | -0.13% | 1,692,127 |
| 24-05-28 | 39.02 | -1.17% | 1,617,400 |
| 24-05-27 | 39.48 | +0.71% | 2,071,700 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
BGI Genomics Co., Ltd. is a leading provider of genomic and proteomic sequencing services primarily to academic institutions, pharmaceutical companies and healthcare providers. The company also provides genomic solutions for biomarker research and development, screening for some of the trisomies present at birth (trisomy 21, trisomy 18 and trisomy 13) and solutions for neo-antigen identification for immuno-oncology research.
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.21% | 2.06B | |
| -38.56% | 8.39B | |
| +0.18% | 3.32B | |
| +9.29% | 2.48B | |
| -24.57% | 1.59B | |
| +32.37% | 1.15B | |
| -7.64% | 704M | |
| +8.42% | 678M | |
| -29.59% | 508M | |
| -6.56% | 273M |
- Stock Market
- Equities
- 300676 Stock
